Skip to main content

Table 1 Clinical demographics of COPD patient subgroups

From: Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD

 

Stable patients

n = 92

Repeatability analysis

n = 36

Paired exacerbation patients

n = 39

Age (years)

71.9 (8.7)

69.3 (8.7)

71.5 (8.0)

FEV1 (L)

1.34 (0.52)

1.47 (0.58)

1.27 (0.55)

FEV1 (% predicted)

54.6 (17.6)

58.1 (18.4)

52.7 (18.8)

FVC (L)

2.86 (0.87)

2.90 (0.77)

2.69 (0.93)

FEV1/FVC (%)

47.6 (13.4)

50.7 (13.1)

48.2 (15.4)

Exacerbation frequency

2.0 [1.0–3.0]

2.0 [1.0–3.0]

2.5 [1.5–3.5]

Smoking pack years

50.0

[28.4–71.5]

45.3

[21.1–62.3]

45.6

[24.5–76.5]

ICS dose

(beclomethasone equivalent μg)

1000

[1000–2000]

1500

[1000–2000]

2000

[1000–2000]

N (%) Male sex

60 (65)

24 (67)

23 (59)

N (%) Current smokers

32 (35)

17 (47)

11 (28)

N (%) Chronic bronchitis

72 (78)

31 (86)

35 (90)

  1. Table shows data for stable COPD patients (n = 92), including subsets of patients used for repeatability experiments (n = 36) and patients with a paired stable and exacerbation sample (n = 39). Parametric data displayed as mean (SD), non-parametric data displayed as median (IQR) and categorical data displayed as N (%)